Supplementary Materials

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Syntheses of LSN3316612, amine precursor 7, and nitro precursor 10.
  • Fig. S2. Chemical structure and 1H, 13C, and 19F NMR spectra for compound 2.
  • Fig. S3. Chemical structure and 1H, 13C, and 19F NMR spectra for LSN3316612.
  • Fig. S4. Chemical structure and 1H, 13C, and 19F NMR spectra for compound 6.
  • Fig. S5. Chemical structure and 1H, 13C, and 19F NMR spectra for amine precursor 7.
  • Fig. S6. Chemical structure and 1H and 13C NMR spectra for compound 9.
  • Fig. S7. Chemical structure and 1H and 13C NMR spectra for nitro precursor 10.
  • Fig. S8. Synthesis of [3H]LSN3316612.
  • Fig. S9. Saturation radioligand binding to brain regions using [3H]LSN3316612.
  • Fig. S10. [3H]LSN3316612 binding to postmortem human AD and control brain tissue.
  • Fig. S11. Radiometabolite analyses for [11C]LSN3316612 and [18F]LSN3316612.
  • Fig. S12. Chromatograms from the radio-HPLC separation of [11C]LSN3316612.
  • Fig. S13. Chromatograms from the radio-HPLC quality control of [11C]LSN3316612.
  • Fig. S14. Chromatograms from the radio-HPLC separation of [18F]LSN3316612.
  • Fig. S15. Chromatograms from the radio-HPLC quality control of [18F] LSN3316612.
  • Table S1. Radioactivity concentration of [3H]LSN3316612 in brain sections of monkey or human.
  • Table S2. Biometric information for human participants.
  • Table S3. Individual VT in four brain regions for all human participants.

[Download PDF]